Cannabics Pharmaceuticals Inc (CNBX) 0.0800 $CNBX
Cannabics Pharmaceuticals Inc. Announces a New Division of Labor in the Corporate Structure
PR Newswire - Fri Oct 09, 8:00AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has announced its execution of an Intellectual Property & Subsidiary Assignment and an Assignment & Assumption of Debt & Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, related party, and a majority holder of 88% of the company.
North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020
M2 - Mon Sep 14, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7wcc2/north_america) has announced the addition of the "North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020" report to their offering. The North America Cannabis market is poised to grow from $ 3.46 billion in 2014 to $20.67 billion in 2020 at an estimated CAGR of 29.80% from 2015 to 2020. Factors like multifaceted applications of cannabis, expansion of licensing strategies, and automated irrigation system among others are driving this market towards growth. This market is also tackling some issues like volatile regulatory framework, absence of market leaders, perception towards marijuana, and environmental hazards among others. Owing to the fragmented supply chain and the presence of black market and perception issues, the cannabis market in North America has been estimated and forecasted strictly for the legal states, both for marijuana and hemp. The following pointers will encompass the scope of the research study and will lend a better understanding to the reader: - The total cannabis market is inclusive of the two primary derivatives namely-marijuana and Industrial Hemp - The market estimation for marijuana includes revenue from the legalized and active markets and Canada, where only medical marijuana is legalized - Certain states have legalized medical and recreational marijuana after 2013, however, there markets are not yet active and therefore, their market shares are not included in the total market size for the benchmark year (2014) - The report includes revenue for the marijuana market for all the active states having market share of above 0.5%. Rest of the state's revenue are clubbed as others - Through the forecast period, the other' states segment will also include the revenue from further states that are anticipated to legalize medical marijuana - The market size by application has been further segmented as applications of marijuana and industrial hemp for better clarity - The report includes the estimates of different entities of the cannabis ecosystem - The report also includes the optimistic revenue estimate for the benchmark year only for the U.S - Tax revenue estimate in case when marijuana is legalized across all the states in the U.S. has also been included Key Topics Covered: 1 Research Methodology, Scope And Coverage 2 Executive Summary 3 Introduction To North American Cannabis Market 4 Key Strategies And Development In The North American Cannabis Market (2013-2015) 5 Market Dynamics 6 North America Cannabis Industry Analysis 7 Regulatory & Legal Framework, Consortiums And Compliances 8 Market Sizing - Estimation, Analysis & Forecast By Derivative 9 Market Sizing- Estimation, Analysis & Forecast By Application 10 Market Sizing Analysis & Forecast, By Market Demand 11 Key Market Players Profiles - 22nd Century Group, Inc. - Abattis Bioceuticals Corporation - Advanced Cannabis Solutions - Affinor Growers - Agrisoft Development Group - Arena Pharmaceuticals, Inc. - Canadian Cannabis Corporation - Canna Brands Inc. - Canna Grow Holdings - Cannabics Pharmaceuticals Inc. - Cannabis Sativa Inc. - Cannabis Science, Inc. - Cannabis Therapy Corporation - Cannacare Docs - Cannavest - Dave - Eaze - Endexx Corporation - Equipment & Infrastructure - Frweed Pro - Grassp - Green Technology Solutions Inc. (Gtso) - Gw Pharmaceuticals - Hemp, Inc. - Information Technology - Insys Therapeutics - Leafly - Mass Roots - Meadow - Medbox, Inc. - Medical Marijuana Inc. - Nestdrop - Omnicanna Health Solutions - Otsuka Pharmaceutical Co. Ltd - Plandai Biotechnology - Privateer Holdings, Inc. - Quantum 9 - Sanofi Pharmaceuticals - Surna, Inc. - Tweed Marijuana Inc. - Weedmaps For more information visit http://www.researchandmarkets.com/research/n7...th_america
XXII: 1.08 (unch), INSY: 25.65 (+0.64), ARNA: 2.19 (+0.14)
DigiPath Labs Clears the Way for Las Vegas' First Cannabis Dispensary
ACCESSWIRE - Fri Aug 21, 11:56AM CDT
SEATTLE, WA / ACCESSWIRE / August 21, 2015 / Nevada legalized medical marijuana in 2001, enabling patients to grow a maximum of 12 cannabis plants at home, but the first dispensary in Southern Nevada selling medical marijuana to the public opened just this month with the passing of Senate Bill 374. The bill clears the way for up to 66 dispensaries and 200 production facilities to operate in the Silver State under the direction of the Department of Health and Human Services.
Cannabics Pharmaceuticals Inc. Announces Increasing Sales of WanaCapsXR Capsules in Every Region of Colorado
PR Newswire - Thu Aug 13, 8:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that first reports from Colorado show that WanaCapsXR cannabis capsules are sold in every region of Colorado.
Cannabics Pharmaceuticals Inc. Files Patent Application Which Covers Novel Personalized Anti-Cancer Treatment
PR Newswire - Thu May 28, 7:10AM CDT
Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an exclusive patent application with the US Patent & Trademark Office (USPTO) on a System and Method for High Throughput Screening of Cancer Cells.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part III
Anthony Cataldo - at Seeking Alpha - Thu Apr 16, 12:51PM CDT
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for the Screening of Potential Anticancer Cannabinoid Compounds
PR Newswire - Mon Apr 06, 7:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for Screening of Potential Anticancer Cannabinoid Compounds
ACCESSWIRE - Thu Apr 02, 6:25PM CDT
BETHESDA, MD / ACCESSWIRE / April 2, 2015 / Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Anorexia Nervosa Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tzf2t/anorexia_nervosa) has announced the addition of the "Anorexia Nervosa Global Clinical Trials Review, H1, 2015" report to their offering. Anorexia Nervosa Global Clinical Trials Review, H1, 2015 provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Anorexia Nervosa Therapeutics Clinical Trials - Sky Growth Acquisition Corporation - Medionics International Inc - Daiichi Sankyo Company, Limited - Cannabics Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - BioGaia AB - AstraZeneca PLC - Arjun Healthcare - Anaborex, Inc. For more information visit http://www.researchandmarkets.com/research/7t...ia_nervosa
AZN: 32.23 (-0.16), BMY: 61.44 (+0.93)
48 Marijuana Stocks - A Post-Mortem: Part II
Anthony Cataldo - at Seeking Alpha - Wed Mar 04, 7:36AM CST
INSY: 25.65 (+0.64), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 87.75 (+0.45), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 87.75 (+0.45), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18), ICN: 21.17 (+0.01)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 87.75 (+0.45), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST
GWPH: 87.75 (+0.45), DE: 79.87 (-1.04), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
Cannabics Pharmaceuticals engages with Mountain High Products in Colorado
PR Newswire - Thu Dec 18, 8:41AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed a letter of engagement with Mountain High Products in Colorado, for the manufacturing and distribution of Cannabics SR medical cannabis products in the Colorado market.
Cannabics Pharmaceuticals Inc. Announces a New Division of Labor in the Corporate Structure
PR Newswire - Fri Oct 09, 8:00AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has announced its execution of an Intellectual Property & Subsidiary Assignment and an Assignment & Assumption of Debt & Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, related party, and a majority holder of 88% of the company.
North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020
M2 - Mon Sep 14, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7wcc2/north_america) has announced the addition of the "North America Cannabis Market: Focus on Application, Derivative, and Region - Estimation & Forecast, 2015-2020" report to their offering. The North America Cannabis market is poised to grow from $ 3.46 billion in 2014 to $20.67 billion in 2020 at an estimated CAGR of 29.80% from 2015 to 2020. Factors like multifaceted applications of cannabis, expansion of licensing strategies, and automated irrigation system among others are driving this market towards growth. This market is also tackling some issues like volatile regulatory framework, absence of market leaders, perception towards marijuana, and environmental hazards among others. Owing to the fragmented supply chain and the presence of black market and perception issues, the cannabis market in North America has been estimated and forecasted strictly for the legal states, both for marijuana and hemp. The following pointers will encompass the scope of the research study and will lend a better understanding to the reader: - The total cannabis market is inclusive of the two primary derivatives namely-marijuana and Industrial Hemp - The market estimation for marijuana includes revenue from the legalized and active markets and Canada, where only medical marijuana is legalized - Certain states have legalized medical and recreational marijuana after 2013, however, there markets are not yet active and therefore, their market shares are not included in the total market size for the benchmark year (2014) - The report includes revenue for the marijuana market for all the active states having market share of above 0.5%. Rest of the state's revenue are clubbed as others - Through the forecast period, the other' states segment will also include the revenue from further states that are anticipated to legalize medical marijuana - The market size by application has been further segmented as applications of marijuana and industrial hemp for better clarity - The report includes the estimates of different entities of the cannabis ecosystem - The report also includes the optimistic revenue estimate for the benchmark year only for the U.S - Tax revenue estimate in case when marijuana is legalized across all the states in the U.S. has also been included Key Topics Covered: 1 Research Methodology, Scope And Coverage 2 Executive Summary 3 Introduction To North American Cannabis Market 4 Key Strategies And Development In The North American Cannabis Market (2013-2015) 5 Market Dynamics 6 North America Cannabis Industry Analysis 7 Regulatory & Legal Framework, Consortiums And Compliances 8 Market Sizing - Estimation, Analysis & Forecast By Derivative 9 Market Sizing- Estimation, Analysis & Forecast By Application 10 Market Sizing Analysis & Forecast, By Market Demand 11 Key Market Players Profiles - 22nd Century Group, Inc. - Abattis Bioceuticals Corporation - Advanced Cannabis Solutions - Affinor Growers - Agrisoft Development Group - Arena Pharmaceuticals, Inc. - Canadian Cannabis Corporation - Canna Brands Inc. - Canna Grow Holdings - Cannabics Pharmaceuticals Inc. - Cannabis Sativa Inc. - Cannabis Science, Inc. - Cannabis Therapy Corporation - Cannacare Docs - Cannavest - Dave - Eaze - Endexx Corporation - Equipment & Infrastructure - Frweed Pro - Grassp - Green Technology Solutions Inc. (Gtso) - Gw Pharmaceuticals - Hemp, Inc. - Information Technology - Insys Therapeutics - Leafly - Mass Roots - Meadow - Medbox, Inc. - Medical Marijuana Inc. - Nestdrop - Omnicanna Health Solutions - Otsuka Pharmaceutical Co. Ltd - Plandai Biotechnology - Privateer Holdings, Inc. - Quantum 9 - Sanofi Pharmaceuticals - Surna, Inc. - Tweed Marijuana Inc. - Weedmaps For more information visit http://www.researchandmarkets.com/research/n7...th_america
XXII: 1.08 (unch), INSY: 25.65 (+0.64), ARNA: 2.19 (+0.14)
DigiPath Labs Clears the Way for Las Vegas' First Cannabis Dispensary
ACCESSWIRE - Fri Aug 21, 11:56AM CDT
SEATTLE, WA / ACCESSWIRE / August 21, 2015 / Nevada legalized medical marijuana in 2001, enabling patients to grow a maximum of 12 cannabis plants at home, but the first dispensary in Southern Nevada selling medical marijuana to the public opened just this month with the passing of Senate Bill 374. The bill clears the way for up to 66 dispensaries and 200 production facilities to operate in the Silver State under the direction of the Department of Health and Human Services.
Cannabics Pharmaceuticals Inc. Announces Increasing Sales of WanaCapsXR Capsules in Every Region of Colorado
PR Newswire - Thu Aug 13, 8:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that first reports from Colorado show that WanaCapsXR cannabis capsules are sold in every region of Colorado.
Cannabics Pharmaceuticals Inc. Files Patent Application Which Covers Novel Personalized Anti-Cancer Treatment
PR Newswire - Thu May 28, 7:10AM CDT
Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an exclusive patent application with the US Patent & Trademark Office (USPTO) on a System and Method for High Throughput Screening of Cancer Cells.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part III
Anthony Cataldo - at Seeking Alpha - Thu Apr 16, 12:51PM CDT
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for the Screening of Potential Anticancer Cannabinoid Compounds
PR Newswire - Mon Apr 06, 7:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for Screening of Potential Anticancer Cannabinoid Compounds
ACCESSWIRE - Thu Apr 02, 6:25PM CDT
BETHESDA, MD / ACCESSWIRE / April 2, 2015 / Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Anorexia Nervosa Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tzf2t/anorexia_nervosa) has announced the addition of the "Anorexia Nervosa Global Clinical Trials Review, H1, 2015" report to their offering. Anorexia Nervosa Global Clinical Trials Review, H1, 2015 provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Anorexia Nervosa Therapeutics Clinical Trials - Sky Growth Acquisition Corporation - Medionics International Inc - Daiichi Sankyo Company, Limited - Cannabics Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - BioGaia AB - AstraZeneca PLC - Arjun Healthcare - Anaborex, Inc. For more information visit http://www.researchandmarkets.com/research/7t...ia_nervosa
AZN: 32.23 (-0.16), BMY: 61.44 (+0.93)
48 Marijuana Stocks - A Post-Mortem: Part II
Anthony Cataldo - at Seeking Alpha - Wed Mar 04, 7:36AM CST
INSY: 25.65 (+0.64), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST
GWPH: 87.75 (+0.45), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST
GWPH: 87.75 (+0.45), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18), ICN: 21.17 (+0.01)
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 87.75 (+0.45), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST
GWPH: 87.75 (+0.45), DE: 79.87 (-1.04), FULL: 3.10 (+0.01), CARA: 14.40 (-0.18)
Cannabics Pharmaceuticals engages with Mountain High Products in Colorado
PR Newswire - Thu Dec 18, 8:41AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed a letter of engagement with Mountain High Products in Colorado, for the manufacturing and distribution of Cannabics SR medical cannabis products in the Colorado market.
